Fact check · Version 1 · Sources checked
“Elamipretide improved walking distance and fatigue in the large phase 3 mitochondrial-myopathy trial.”
The Peptide Field explains research. Its pages are not independently medically reviewed, and they do not diagnose, prescribe, or recommend treatment.
Misleading
This statement leaves out a limit that changes its meaning.
The 24-week MMPOWER-3 trial did not meet its main goals for six-minute walk distance or fatigue compared with placebo.
- What this answer is based on
- This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- The 218 adults with genetically confirmed primary mitochondrial myopathy studied in MMPOWER-3 for 24 weeks. These limits show which substance, product, people, use, place, and time the answer covers. A different product or situation can have a different answer.
- Topic
- What a study measured about people's health, symptoms, or ability to function.
Sources for this fact check
- Sources checked by
- Site editor · Editorial review